Low incidence of anti-osteoporosis treatment after hip fracture.

peer reviewed ; BACKGROUND: Following hip fracture, pharmacologic treatment can reduce the rate of subsequent fragility fractures. The objective of the present study was to assess the proportion of patients who are managed with bisphosphonates or selective estrogen-receptor modulators after hip fracture and to evaluate, among those managed with alendronate, the twelve-month compliance and persistence with treatment. METHODS: Data were gathered from health insurance companies and were collected by AIM (Agence Intermutualiste) for the Belgian National Social Security Institute (INAMI). We select... Mehr ...

Verfasser: Rabenda, Véronique
Vanoverloop, Johan
Fabri, Valerie
Mertens, Raf
Sumkay, Francois
Vannecke, Carine
Deswaef, Andre
Verpooten, Gert A
Reginster, Jean-Yves
Dokumenttyp: journal article
Erscheinungsdatum: 2008
Verlag/Hrsg.: Journal of Bone and Joint Surgery
Schlagwörter: Aged / Alendronate/therapeutic use / Belgium/epidemiology / Bone Density Conservation Agents/therapeutic use / Cohort Studies / Databases / Factual / Diphosphonates/therapeutic use / Female / Hip Fractures/epidemiology/therapy / Hospitalization/statistics & numerical data / Humans / Middle Aged / Osteoporosis / Postmenopausal/complications/prevention & control / Patient Compliance/statistics & numerical data / Physician's Practice Patterns/statistics & numerical data / Retrospective Studies / Selective Estrogen Receptor Modulators/therapeutic use / Human health sciences / General & internal medicine / Sciences de la santé humaine / Médecine générale & interne
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26584600
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://orbi.uliege.be/handle/2268/20332